|Bid||4.0600 x 1200|
|Ask||4.5200 x 2900|
|Day's Range||4.2000 - 4.4626|
|52 Week Range||3.7790 - 12.5000|
|Beta (5Y Monthly)||1.94|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||12.75|
NEW YORK, Jan. 20, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- IBN (InvestorBrandNetwork), a multifaceted financial news and publishing company for private and public entities, today announces that Chris Bunka, Chairman and CEO of Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently appeared on the EDGE Podcast, a series focused on providing the business owner's playbook about the inner game of building a successful business and giving listeners the e
"Cannabinoids have the potential to prevent as well as treat infection by SARS-CoV-2"KELOWNA, BC / ACCESSWIRE / January 18, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, comments on an independent January 10 study, available here, that discovered that "Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants".
• Dosing is expected to begin by April, 2022KELOWNA, BC / ACCESSWIRE / December 29, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to report that Independent Review Board ("IRB") approval has been received ahead of schedule for its upcoming DehydraTECH-CBD human hypertension study HYPER-H21-4.